15 Stocks to Double In 2017: FEYE, GM, CHK, MRO, & SRPT Stock

- January 9, 2017

stocks_to_double

In Part 3 of our 3-part series, we look at the last five stocks we believe can double in 2017. As explained in Part 1 and Part 2, these stock selections are not without risk. That’s why we have adopted a number system between 0-10 to gauge just how likely these triple digit gains are, in 2017.

So while Sarepta Therapeutics Inc (NASDAQ:SRPT), General Motors Company (NYSE:GM), Chesapeake Energy Corporation (NYSE:CHK), Marathon Oil Corporation (NYSE:MRO), and FireEye Inc (NASDAQ:FEYE) all have the potential to double in 2017, all have one or many risks that could prevent proper appreciation.

The big question is will the companies overcome these risks and ultimately soar higher? That question will be explored.

Stocks to double: SRPT stock

srpt-stockSarepta Therapeutics (NASDAQ:SRPT) is one of the more controversial biotechs in the market, and SRPT stock reflects that fact well.

Sarepta’s drug, Exondys 51, got approved with very little data, and a lot of patient and political pressure on the FDA. Sarepta still has to do a post approval study, and many insurers are giving the company a hard time to cover the pricey drug, $300,000/year.

Still, there are no other approved treatments for DMD, and based on our sources physician’s have had success at getting insurers to approve and cover Exondys 51. Like all Orphan, high priced drugs, it just takes times, and often times a dedicated team who works exclusively with insurance companies and PBMs.

With that said, Sarepta has the advantage of knowing that DMD patients are lining up to use Exondys 51, as families have waited for its FDA approval for a long time.

bnl_stock_research

Even with reimbursement issues, we believe SRPT could very well have 750 patients on Exondys 51 in 2017. That would put sales on a $225 million run rate, and admittedly, that could be very conservative.

Given the volatility in SRPT stock coupled with the likelihood for accelerated script and sales growth (with low costs), SRPT stock could double. And remember, many believe Exondys will be a billion dollar drug. Therefore, 100% SRPT stock gains could be the start of something much bigger.

The one drawback is uncertainties surrounding the FDA and insurance companies. Thus, I give SRPT stock a score of “7”, reflecting its likelihood to really double in 2017.

This entry was posted in BNL Reports, Hot Stocks, Members Bookmark the permalink.
RSS feed for this post. Post a comment or leave a trackback: Trackback URL.

One Trackback

  1. By queen size bed guard rail on March 4, 2017 at 6:05 pm

    queen size bed guard rail

    15 Stocks to Double In 2017: FEYE, GM, CHK, MRO, & SRPT Stock

Post a Comment

You must be logged in to post a comment.







Join the 100s Who Beat the Market with a BNL Membership

See What Current Members Are Saying

My Complete Access BNL Membership Includes

  • No contract. Guaranteed results. Cancel anytime.
  • Unrivaled Performance. The BNL Portfolio has outperformed the S&P 500 by 150% since October 1, 2015
  • Access. You know what goes in the BNL Portfolio, David’s Dividend Portfolio, and Eddy’s Options.
  • Alerts. You know when a trade is made in all three managed portfolios with application, text, and email alerts
  • Transparency. Verifiable trade records for the BNL Portfolio, David’s Dividends, & Eddy’s Options
  • Research. We have coverage on more than 50 companies
  • Results. Our 10 highest rated stocks outperformed the market by 134% last year
  • Live Chat. Join 100s of other members in an exclusive Members Only section with Chat
  • Growth. We are the fastest growing financial research platform in our industry.
  • Build My Portfolio. You give us your goals, we help you get there
  • Premium Content. Unlock hidden sections in each article. You also get Value of the Month selections and BNL Research Reports.
  • Community. We have professionals and beginners; retirees and college students; the 99% & 1%, but here, we are all equal.


Like what you see? Sign up for our newsletter and get the latest stock picks straight to your email!